ALS-Lipids Link, Eye Disease and Heightened Dementia Risk; Parkinson’s and NSAIDs

Elevated levels of HDL and apolipoprotein A1 were linked to a lower risk of amyotrophic lateral sclerosis (ALS), U.K. Biobank data showed. (Journal of Neurology, Neurosurgery, & Psychiatry)

Also from the U.K. Biobank cohort: age-related macular degeneration, cataracts, and diabetes-related eye disease were tied to a heightened risk of dementia. (British Journal of Ophthalmology)

Amyloid produced in the liver caused neurodegeneration in a mouse study. (PLOS Biology)

Nearly 8% of patients with opioid use disorder died within 12 months of being discharged from a general hospital admission. (Journal of Addiction Medicine)

The FDA announced that Jacobus Pharmaceutical recalled three lots of amifampridine (Ruzurgi) 10 mg tablets, a drug used to treat Lambert-Eaton myasthenic syndrome in children, after lab tests showed they were contaminated with yeast, mold, and aerobic bacteria.

Cumulative high exposure to non-steroidal anti-inflammatory drugs (NSAIDs) was not associated with Parkinson’s disease incidence, a study in Norway showed. (PLOS One)

A transcriptome-wide association study identified 18 genes significantly associated with Parkinson’s. (npj Parkinson’s Disease)

T-cell specificity was tied to disease heterogeneity in multiple sclerosis (MS). (Neurology Neuroimmunology & Neuroinflammation)

Six months after colorectal cancer diagnosis, overall and cancer-specific survival was lower in MS patients than in people without MS. (Neurology)

Axsome Therapeutics said the FDA accepted the new drug application for AXS-07, a meloxicam-rizatriptan combination for acute migraine treatment, with a decision expected in April 2022.